Skip to main content

Featured

5 Things to Know Today: US Inflation Day, Canada’s Job Losses and Oil Near $106 | Oct. 14, 2026

  Canadian Money Brief  |  Wednesday, October 14, 2026 Good morning. The biggest number of the day lands at 8:30 a.m. ET, and it could shape where mortgage rates and the loonie go next. Here are the five things worth knowing before you start your day. 1 US inflation report lands at 8:30 a.m. ET September U.S. CPI is the last major inflation reading before the Fed meets Oct. 27–28. Economists expect headline inflation to climb to roughly 3.6%–3.7% from 3.4% in August, a gasoline-driven jump of about 0.6% on the month, while core inflation is seen cooling to around 0.2% month over month. The Fed raised its target range to 3.75%–4.00% on Sept. 16, but September payrolls added just 29,000 jobs, and markets now see roughly a one-in-four chance of another hike in October, with December still largely priced in. What it means for you: A hotter-than-expected print can push bond yields higher, and Canadian fixed mortgage rates follow the 5-year bond. A cooler one eases the pressu...
Post a Comment
Read more

article

Labels

Alzheimer’s vaccines get a boost from new drug approval

 

After decades of disappointment and controversy, the field of Alzheimer’s disease research has finally seen a breakthrough with the approval of the first drug that targets the underlying pathology of the condition. 

Aducanumab, a monoclonal antibody that clears amyloid plaques from the brain, was granted accelerated approval by the US Food and Drug Administration in June 2021, despite mixed results from clinical trials and objections from some experts. 

The drug’s approval has rekindled interest in other therapeutic approaches that aim to prevent or slow down the progression of Alzheimer’s, such as vaccines that stimulate the immune system to attack amyloid or tau, another protein that accumulates in the brains of people with the disease. 

Several vaccine candidates are currently in various stages of development and testing, and some researchers are optimistic that they could offer a more effective and convenient way to treat Alzheimer’s than infusions of antibodies.


Labels:

Comments

Post a Comment